Nairobi, Kenya, October 24, 2022— IFC's Africa Medical Equipment Facility, which helps healthcare providers in sub-Saharan Africa access medical equipment and supplies, today welcomed laboratory diagnostic equipment provider bioMérieux to its growing roster of world-class partners.
France-headquartered bioMérieux's participation in the
IFC-led facility will expand opportunities for hospitals and stand-alone laboratories in Africa to obtain and service
in vitro diagnostic equipment used to diagnose infectious diseases.
"bioMérieux Africa's commitment to improve global public health by fighting against infectious diseases took another important step forward today. The agreement signed with IFC will directly benefit numerous laboratories, hospitals and the healthcare ecosystem as a whole," said Sindé Chekete, bioMérieux Senior Vice President, Africa Region.
"IFC is working with bioMérieux to build a stronger, more resilient health system across Africa that includes deploying innovative financing solutions to enable more of Africa's smaller private medical providers to purchase and maintain laboratory equipment," said Henrik Elschner Pedersen, IFC's Africa Director for Manufacturing, Agribusiness and Services.
The Africa Medical Equipment Facility (AMEF) works with partner financial institutions and medical equipment manufacturers to make affordable, long-term funding available to African healthcare providers, which often struggle to secure financing, so they can purchase equipment needed to deliver quality care to patients.
AMEF also helps these smaller health providers access procurement training and equipment servicing thanks to its partnership with bioMérieux and other partners in the facility.
Launched in April 2021, AMEF is currently active in Côte d'Ivoire and Kenya and plans to expand to Cameroon, Rwanda, Senegal, Tanzania, and Uganda. Partner financial institutions include the
Co-operative Bank of Kenya and
NSIA Banque Côte d'Ivoire.
ABOUT IFC
IFC—a member of the World Bank Group—is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2022, IFC committed a record $32.8 billion to private companies and financial institutions in developing countries, leveraging the power of the private sector to end extreme poverty and boost shared prosperity as economies grapple with the impacts of global compounding crises. For more information, visit www.ifc.org.
Stay Connected
www.facebook.com/IFCwbg
www.twitter.com/IFC_org
www.youtube.com/IFCvideocasts
www.ifc.org/SocialMediaIndex
www.instagram.com\ifc_org
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of
in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2021, revenues reached €3.4 billion, with over 90% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
www.biomerieux.com.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
